
Paul Roach
Nuclear Medicine Specialist, AustraliaPresentation Title:
Rhenium-SCT radionuclide treatment of skin cancers: Logistical challenges for nuclear medicine centres
Abstract
Background: The epidermal radioisotope therapy Rhenium-SCT (Skin Cancer Therapy) utilising the non-sealed beta emitter rhenium-188 is being increasingly used for the treatment of various non-melanoma skin cancers (NMSC). It has particular benefits for lesions that are difficult to treat with surgery or external beam radiation therapy, especially on the nose or ears. There are however various challenges that must be overcome for Nuclear Medicine practices and practitioners using this treatment.
Results: Based on experience to date, the following are key issues that should be addressed when treatments are undertaken. Firstly, nuclear medicine specialists applying the paste should upskill in the diagnosis and management of NMSC. Secondly, practitioners applying the foil on the skin should practice the technique of foil application, which is generally the most challenging part of the procedure. Thirdly, all staff involved should be trained and understand the software used to calculate the administered dose, typically 50Gy as overtreatment or undertreatment can occur if there are dose calculation errors. Finally, all staff present (technologists, medical practitioners, nurses) must ensure that radiation safety procedures are carefully followed by all and there are sufficient staff to ensure that the patient dose not touch the radioactive paste until fully dry (typically ~5 minutes post application).
Conclusions: SCT of NMSC is a promising treatment for many patients unsuited to surgery or external beam radiotherapy. Appropriate patient selection, upskilling of all staff involved, and careful attention to radiation safety precautions is essential to ensure optimal outcomes.
Biography
Paul Roach is an experienced nuclear medicine specialist based in Sydney, Australia